We are delighted to announce a new addition to our growing team, Sheila Soriano

We are delighted to announce a new addition to our growing team, Sheila Soriano. In 2019, she graduated in Chemistry from the University of Zaragoza, where she specialized in Analytical Sciences, oriented towards research and innovation, both from a chemical and biological point of view. In 2018, during her Erasmus studies in Italy, she had the … Read more

Different awards and grants recognize ARTHEx’s efforts to start up an innovative treatment for DM1

We are proud and overjoyed, the hard work of the ARTHEx’s team has earned recognition after our first-anniversary celebration. This month has been fascinating, bringing us several grants and awards at regional, national, and international levels. The €250K funding from the Neotec program has been a resounding success. Indeed, this is the most prestigious grant … Read more

Eric Marcusson joins ARTHEx’s  Scientific Advisory Board

September 2020: ARTHEx expands its Scientific Advisory Board with the appointment of Eric G. Marcusson, who has an extensive experience of more than 20 years in preclinical drug development of RNA therapeutics. Currently, Dr. Marcusson has his own consultancy firm to provide expert advice to start-ups, pharma industry and venture capitalists. He is also co-founder … Read more

Dr Nicholas Jonhson, new Chief Medical Advisor

August 2020: After closing a funding round of €4.25 million, ARTHEx confirms the professionalization of its team with the appointment of Nicholas Johnson, M.D., M.Sci., FAAN, as the Chief Medical Advisor of the company. Dr. Johnson is a physician specialist in DM1,  associate professor of Neurology and Human and Molecular Genetics, vice chair of research … Read more

Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology

Funding will help advance development of company’s Myotonic Dystrophy therapy Valencia and Barcelona, Spain, and Paris, France, July 23, 2020 – Arthex Biotech (ARTHEx), a preclinical stage life sciences company focused on the development of the next generation antisense RNA therapies for the treatment of Myotonic Dystrophy Type 1 (DM1), today announces it has closed … Read more